Reports

Jul 2023

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

300,00€

Jul 2023

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

400,00€

Jul 2023

Adalimumab (Humira) Biosimilars Pipeline Review

400,00€

Jun 2023

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

300,00€

Jun 2023

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

300,00€

Jun 2023

Ranibizumab (Lucentis) Biosimilars Pipeline Review

300,00€

Jun 2023

Aflibercept (Eylea) Biosimilars Pipeline Review

300,00€

Jun 2023

Ustekinumab (Stelara) Biosimilars Pipeline Review

300,00€

Jun 2023

TSLP Pipeline Review

300,00€

Mar 2023

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

120,00€

Feb 2023

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

1.600,00€

Feb 2023

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

1.800,00€

Nov 2022

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

2.350,00€

Jul 2022

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

2.550,00€

1.800,00€

Jul 2022

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

600,00€

Jun 2022

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

1.050,00€

May 2022

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

400,00€

May 2022

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

500,00€

Mar 2022

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

2.450,00€

Mar 2022

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

100,00€

Oct 2021

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

4.400,00€

2.200,00€

Oct 2021

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

2.250,00€

Jul 2021

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

2.150,00€

Mar 2021

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

100,00€

May 2020

Report Package: “Drug the Undruggable” Technologies

8.250,00€

4.125,00€

Report categories

Antibody & Protein Sales

Antibody Technologies

Biosimilar Antibodies & Proteins

CAR T-Cells

Drug the Undruggable Technologies

Immuno-Oncology

mRNA Vaccines & Therapeutics

NK Cells & CAR Macrophages

Pipeline Database

RNA-Targeted Therapeutics

Target Pipelines

TCR T-Cells and Antibodies

Therapeutic Antibodies

Therapeutic Proteins & Peptides